How to bid on Lab Testing Services for clonoSEQ at Pittsburgh VA Medical Center

What the VA is buying and why it matters

The Department of Veterans Affairs (VA) Pittsburgh VA Medical Center needs clonoSEQ Measurable Residual Disease (MRD) Testing services. This is a specialized molecular test used for detecting residual disease in patients with certain blood cancers like multiple myeloma and leukemia.

The VA estimates needing 100 tests annually under a five-year, firm-priced contract. While the VA believes Adaptive Biotechnologies is the sole provider, this notice allows other firms to demonstrate their capability to perform this specific testing.

Key dates and what happens at the deadline

Responses to this notice are due by Monday, August 10, 2026, at 8:00 AM Eastern Standard Time. No submissions will be accepted after this date and time.

All responses must be submitted via email to Mrs. Mickeya Linzie at [email protected]. The government will evaluate responses to determine if there are other firms capable of meeting the requirement.

Who this opportunity suits

This opportunity is for firms in the healthcare sector, specifically those with expertise in medical laboratory services and advanced molecular testing. The NAICS code for this acquisition is 621511 (Medical Laboratories), with a size standard of $41.5 million.

It is particularly relevant for companies that can provide clonoSEQ MRD testing or an equivalent, proprietary, FDA-cleared, and CLIA-validated molecular test for MRD detection in the specified conditions.

How to respond to this notice

To respond, you must submit a written notification and capability statement by the deadline. Your submission should clearly indicate if you are the direct supplier or service provider.

Include supporting evidence in sufficient detail to show your ability to perform the requirement. This includes relevant experience, applicable contract numbers, total contract dollar amounts, contract periods of performance, details of relevant services, and customer points of contact with phone numbers and email addresses.

Your response must also include your Company Name, SAM UEI Number, Company's Address, Point of Contact Information (title, phone number, and email address), and Business Size.

Tips for preparing a competitive response

Even though this is a sole source notice, a strong capability statement can influence the government's decision. Focus on clearly demonstrating how your firm meets or exceeds the specific requirements for clonoSEQ MRD testing.

Provide concrete examples of past performance with similar specialized laboratory services. Quantify your experience where possible, such as the number of tests performed or the types of facilities served. Ensure all requested company information is accurately provided and easy to locate within your submission.